Amicus completes enrollment in late-stage study of SD-101 in rare skin blistering disorder; shares up 2%

|About: Amicus Therapeutics, Inc. (FOLD)|By:, SA News Editor

Amicus Therapeutics (FOLD +2.2%) hits the enrollment target in its Phase 3 clinical trial, ESSENCE, evaluating topical medicine SD-101 for the treatment of epidermolysis bullosa, a rare inherited disorder characterized by blistering or erosion of the skin. Top-line data are expected in Q3.

The company obtained the rights to the product candidate via its 2015 acquisition of Scioderm.

Previously: Amicus Therapeutics buys Scioderm for up to $847M (Aug. 31, 2015)